Innovation

Prelude Therapeutics Cuts Quarterly Net Loss 55% As R&D Spending Falls 38%

By Amit Chowdhry ● Aug 22, 2026

Prelude Therapeutics reduced its second-quarter 2026 net loss by approximately 55% year-over-year as research and development spending declined sharply following the pausing of previous clinical programs and a workforce reduction. Net loss narrowed to $13.9 million, or $0.14 per share, from $31.2 million, or $0.41 per share, in the prior-year quarter.

John B. Sanfilippo: Sales Volume Returns To Growth After Five Quarters, But EPS Falls 38%

By Amit Chowdhry ● Aug 22, 2026

John B. Sanfilippo & Son returned to companywide sales-volume growth during its fiscal fourth quarter of 2026 after five consecutive quarterly declines, but higher costs and operational challenges pressured profitability and drove diluted EPS down 38%. Fourth-quarter net sales increased 4.2% to $280.4 million, while sales volume increased 1.4% to 87.4 million pounds.

Alvotech Targets Three U.S. Biosimilar Decisions In Q4 After FDA Manufacturing Inspection Closes

By Amit Chowdhry ● Aug 22, 2026

Alvotech is targeting a potentially significant fourth quarter of 2026, with U.S. regulatory decisions anticipated for three biosimilar programs following resubmissions to the FDA and the closure of a recent inspection of its manufacturing facility in Reykjavik.

Flex LNG: Net Income Jumps 130% Sequentially As Middle East Volatility Boosts Spot-Exposed Vessels

By Amit Chowdhry ● Aug 22, 2026

Flex LNG reported a sharp sequential improvement in second-quarter 2026 earnings as heightened volatility in global energy markets created profitable opportunities for the company's spot-exposed LNG carriers.

Jaguar Health: Sales And Marketing Spending Reduced More Than 99% After Future Pak Licensing Deal

By Amit Chowdhry ● Aug 22, 2026

Jaguar Health reduced quarterly sales and marketing spending by more than 99% after transferring U.S. commercial responsibility for Mytesi and Canalevia-CA1 to Future Pak, substantially changing the company's cost structure and revenue model.

Exyn: Gross Margin Expands 630 Basis Points Despite 32% Revenue Decline As Software Mix Increases

By Amit Chowdhry ● Aug 22, 2026

Exyn Technologies reported a substantial improvement in second-quarter gross margin despite lower revenue as a growing contribution from software and subscription sales shifted the company's business mix toward higher-margin offerings.

Cosmos Health: Revenue Rises 29% To Record, But Net Loss More Than Doubles To $6.1 Million

By Amit Chowdhry ● Aug 22, 2026

Cosmos Health reported record second-quarter revenue in 2026, but its GAAP net loss more than doubled as financing-related fair-value adjustments outweighed improving adjusted operating performance. Revenue increased 28.8% to a record $18.99 million from $14.75 million.

Beam Global: Revenue Jumps 174% Sequentially As International Sales Approach Half Of Revenue

By Amit Chowdhry ● Aug 22, 2026

Beam Global reported a sharp sequential rebound in second-quarter revenue as its international operations became an increasingly significant part of the business.

Accuray: Service Revenue Rises 6% To Nearly 60% Of Sales As Product Revenue Plunges 42%

By Amit Chowdhry ● Aug 22, 2026

Accuray's revenue mix shifted sharply toward recurring service revenue during its fiscal fourth quarter of 2026 as product sales declined 42% while service revenue continued growing. Fourth-quarter total revenue fell 21% to $100.9 million from $127.5 million.

Circle8: Revenue More Than Triples After European Acquisition, But Gross Margin Falls 370 Basis Points

By Amit Chowdhry ● Aug 22, 2026

Circle8 Group's second-quarter revenue more than tripled after it acquired European technology staffing platform Circle8 Group B.V., but the expansion came with significantly lower consolidated gross margins.

Virtuix Expands Omni One Into Tesla Optimus, NASA And U.S. Military Applications

By Amit Chowdhry ● Aug 22, 2026

Virtuix Holdings is expanding its Omni One full-body virtual-reality platform well beyond consumer gaming, with recent deployments and development programs spanning Tesla's Optimus humanoid robot program, NASA exploration simulations, and multiple U.S. military applications.

UNIFI: Gross Margin Swings 1,070 Basis Points As Adjusted EBITDA Turns Positive

By Amit Chowdhry ● Aug 22, 2026

UNIFI delivered a significant profitability turnaround during the fiscal fourth quarter of 2026, with gross margin improving by more than 1,000 basis points and adjusted EBITDA swinging into positive territory despite only modest revenue growth. Fourth-quarter net sales increased 4.1% to $144.2 million from $138.5 million. Gross profit, however, improved dramatically to $14.3 million from a gross loss of $1.1 million in the prior-year period.

Marti: Gross Margin Expands Nearly 1,950 Basis Points As Revenue Jumps 141% And Adjusted EBITDA Turns Positive

By Amit Chowdhry ● Aug 22, 2026

Marti Technologies delivered a major improvement in profitability during the second quarter of 2026 as rapid revenue growth, higher platform monetization, and operating leverage pushed gross margin to a record level and adjusted EBITDA into positive territory.